Revlimid for AML with 13q abnormality.
by
Mark LevinPosted
Sat 21 Nov 2009 10:02pm
Revlimid is a derivative of thalidomide with less toxic side effects. A multicenter U.S. trial has reported hematologic activity of Revlimid in patients with myelodysplastic syndromes (MDS). The U.S. Food and Drug Administration has approved Revlimid for the treatment of low- to intermediate-risk MDS in patients who are transfusion-dependent as ...
Read on »
